Translational Drug Development (TD2)

TD2 is excited to share our latest blog post: Top Trends in ADC Drug Development. Dive into the advancements and innovations shaping the future of Antibody Drug Conjugates (ADCs) in cancer therapy. • In Vitro Assays: Discover the crucial techniques for evaluating ADC efficacy and safety. • In Vivo Testing: Learn about the indispensable role of animal models in ADC development. • Combination Therapy: Explore how ADCs are being combined with other treatments for enhanced outcomes. • Technological Advancements: Stay updated on the latest innovations in linker technology, bioconjugation, and more. 🔬 Read the full blog post here: https://hubs.li/Q02GkW_C0 #TD2 #Oncology #ADCs #CancerTherapy

We're thrilled to announce that our very own Tara Franks, MBA, Chief Operating Officer of TD2, has been honored as a 2024 Phoenix Titan 100 award recipient! The Titan 100 program celebrates Phoenix’s top 100 CEOs and C-level executives, recognizing their exceptional leadership, vision, and passion. Tara's innovative approach and strategic acumen have been instrumental in driving TD2’s growth and success, particularly in areas such as pancreatic cancer, cell therapy, and glioblastoma. Join us in congratulating Tara on this well-deserved recognition! She will be honored at the awards ceremony on September 26th, 2024, at the beautiful Chateau Luxe. Read more about Tara's achievements and the Titan 100 program here: https://hubs.li/Q02G8-pd0 #Titan100 #Oncology #TD2

Today's the day, TD2 is live in Boston at Clinical Trials in Oncology East Coast! Stop by to learn about our latest advancements in oncology research or follow the link to schedule a meeting: https://hubs.li/Q02FhSPg0

July is dedicated to raising awareness about Sarcoma and Bone Cancer! This month it's important to highlight advancements that bring hope to young patients battling these devastating diseases. We'd like to share Europe's new clinical guidelines are set to improve the treatment of childhood bone cancer. Developed by leading researchers, including Dr. Darrell Green from the University of East Anglia, these guidelines will shift treatment from untargeted chemotherapy to precision medicine, aiming to provide personalized and effective treatments with reduced side effects. 🔗 Read more about these guidelines and their impact on childhood bone cancer treatment here: https://hubs.li/Q02Fj7jN0

Excited to announce that TD2 will be a part of the 13th Clinical Trials in Oncology East Coast in Boston! If you are attending and would like to meet in person, reach out to schedule a meeting here: https://hubs.li/Q02DRpn-0

🚀 Advancing ADC Drug Development with TD2! 🚀 At TD2, we have developed a suite of services specializing in Antibody Drug Conjugate (ADC) development. ADCs are transforming cancer therapy by targeting cancer cells with precision, minimizing harm to healthy tissues. https://hubs.li/Q02DC6M_0 🔬 How can TD2 accelerate your ADC development? ~Comprehensive Preclinical Evaluation: From in vitro assays to in vivo models, we rigorously test your ADCs for safety and efficacy. ~Pharmacokinetics & Toxicology Expertise: We optimize dosing regimens and identify potential adverse effects early. ~Advanced Bioanalytical Services: Our comprehensive flow cytometry ensures precise characterization of your ADCs. ~Regulatory Support: We provide strategic guidance to navigate the regulatory landscape smoothly. Collaborative Approach: We tailor solutions to meet your needs, accelerating your path from discovery to clinical success. At TD2, we're more than a service provider; we're your partner in advancing cancer therapies. Let's work together to bring innovative ADC treatments to patients. #ADC #DrugDevelopment #OncologyResearch #CancerTherapy #TD2 #Pharma #Biotech #LifeSciences #Innovation #ResearchAndDevelopment

TD2 is proud to announce our collaboration with Atropos Health, granting us access to the Atropos Evidence Network, the largest federated healthcare data network with over 300 million patients. This partnership will leverage high-quality real-world data to optimize clinical trial designs and improve patient outcomes. Discover how we're advancing precision oncology through this innovative collaboration. Read more about it here: https://hubs.li/Q02D2ScF0 #OncologyResearch #ClinicalTrials #TD2 #AtroposHealth

Advance Your Oncology Research with TD2's Validated Tumor Cell Lines! Are you looking to elevate your cancer research to the next level? Our thoroughly characterized and validated tumor cell lines are designed to provide unparalleled reproducibility and reliability. 🔬 Predict Response: Identify drug sensitivity and resistance profiles with our robust cell line models. 🧪 Apply Proven Context: Enhance your study design with detailed mutational context and analysis. 🤝 Expert Support: Our dedicated team of experts is here to assist with selection, troubleshooting, and optimization, helping you accelerate your research. Transform your experiments with a solid foundation. Visit our download page to get started today: https://hubs.li/Q02C830d0 #Oncology #CancerResearch #ClinicalResearch #TD2

Check out our latest blog post: "Unlocking Insights: Top 5 Reasons to Incorporate Orthotopic GBM PDX Models into Your Preclinical Evaluation." Discover how these models are transforming glioblastoma multiforme (GBM) research by enhancing clinical relevance and therapeutic development. Read the full blog here: https://hubs.li/Q02BXq_L0 Our expertise at TD2 ensures robust preclinical studies, driving novel therapies and improving patient outcomes. #OncologyResearch #GBM #TD2

Celebrating National Cancer Survivorship Month with TD2 🎗️ This June, we honor the incredible strength and resilience of cancer survivors around the world. At TD2, we're dedicated to advancing oncology research and improving the lives of those affected by cancer. Join us in celebrating National Cancer Survivor Month and making a difference! Here’s how you can help celebrate National Cancer Survivor Month: - Let the cancer survivors in your life know how thrilled you are to celebrate this month with them. - Donate to organizations advancing cancer research, advocacy, and education. - Spread the word that June is National Cancer Survivor Month by sharing this post on social media. Together, we can make a meaningful impact. 💪 #CancerSurvivorshipMonth #TD2Oncology #CancerResearch #CelebrateSurvivors